Papavasiliou P S, McDowell F H, Rosal V, Miller S T
Arch Neurol. 1979 Oct;36(10):624-6. doi: 10.1001/archneur.1979.00500460058007.
To investigate further the role of growth hormone (GH) on the cerebral effects of levodopa, human somatotropin (human growth hormone) was administered to four patients with parkinsonism with varying response to chronic levodopa therapy. The doses of somatotropin (5 IU) were administered on alternate days for four days, and the effects of this hormone on the patient's symptomatic control, dyskinesia, plasma GH, and dopa levels were evaluated and compared with those of patients receiving saline injections. We have demonstrated that administration of exogenous human somatotropin, even during marked and sustained elevations of plasma GH levels, does not alter the therapeutic or side effects of levodopa therapy. With one exception, plasma dopa levels after human somatotropin administration remained unchanged. We conclude that neither the endogenous increases of GH in response to levodopa nor those attained following human somatotropin administration modify in any consistent way the therapeutic and side effects of chronic levodopa therapy, and that the episodic releases of GH in response to levodopa occur independently of its cerebral effects.
为了进一步研究生长激素（GH）在左旋多巴对大脑影响方面的作用，对四名帕金森病患者使用了人生长激素（人类生长激素），这些患者对慢性左旋多巴治疗的反应各不相同。生长激素剂量（5国际单位）每隔一天给药一次，共给药四天，并评估该激素对患者症状控制、运动障碍、血浆生长激素和多巴水平的影响，并与接受盐水注射的患者进行比较。我们已经证明，即使在血浆生长激素水平显著且持续升高期间给予外源性人生长激素，也不会改变左旋多巴治疗的疗效或副作用。除了一个例外，给予人生长激素后血浆多巴水平保持不变。我们得出结论，无论是左旋多巴引起的内源性生长激素增加，还是给予人生长激素后达到的生长激素增加，都不会以任何一致的方式改变慢性左旋多巴治疗的疗效和副作用，并且左旋多巴引起的生长激素的间歇性释放独立于其对大脑的影响而发生。
